AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Tarsus Pharmaceuticals, Inc. Director's Dealing 2021

Aug 10, 2021

31511_dirs_2021-08-10_9a15cf62-c194-4881-b1b5-24c4f53d9924.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Tarsus Pharmaceuticals, Inc. (TARS)
CIK: 0001819790
Period of Report: 2021-08-06

Reporting Person: Ackermann Michael (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-08-06	Common Stock	S	3129	$25.00	Disposed	1228669	Direct
2021-08-09	Common Stock	S	700	$25.00	Disposed	1227969	Direct

Footnotes

F1: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2021.